Prior Oral Contraceptive Use and Longer Term Mortality Outcomes in Women with Suspected Ischemic Heart Disease

被引:8
作者
Barsky, Lili [1 ]
Shufelt, Chrisandra [1 ]
Lauzon, Marie [1 ]
Johnson, B. Delia [2 ]
Berga, Sarah L. [3 ]
Braunstein, Glenn [1 ]
Bittner, Vera [4 ]
Shaw, Leslee [5 ]
Reis, Steven [2 ]
Handberg, Eileen [6 ]
Pepine, Carl J. [6 ]
Bairey Merz, C. Noel [1 ]
机构
[1] Cedars Sinai Smidt Heart Inst, Barbra Streisand Womens Heart Ctr, 127 S San Vicente Blvd,Suite A3600, Los Angeles, CA 90048 USA
[2] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA
[3] Univ Utah, Div Reprod Endocrinol, Dept Obstet & Gynecol, Salt Lake City, UT USA
[4] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA
[5] Weill Cornell Med & New York Presbyterian Hosp, Dalio Inst Cardiovasc Imaging, New York, NY USA
[6] Univ Florida, Dept Med, Div Cardiol, Gainesville, FL USA
关键词
oral contraceptive; WISE; nonobstructive coronary artery disease; mortality; CORONARY-ARTERY-DISEASE; MENOPAUSAL HORMONE-THERAPY; SYNDROME EVALUATION WISE; MYOCARDIAL-INFARCTION; NATIONAL-HEART; RISK; LUNG;
D O I
10.1089/jwh.2020.8743
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Previous Women's Ischemia Syndrome Evaluation (WISE) work demonstrated prior oral contraceptive (OC) use was associated with lower coronary artery disease (CAD) in women with suspected ischemia. The association of prior OC use with longer term all-cause and cardiovascular disease (CVD) mortality is unclear. Methods: WISE women undergoing coronary angiography for suspected ischemia (enrolled 1996-2001) with prior OC use history and 10-year follow-up data were analyzed. A blinded core laboratory assessed atherosclerotic CAD severity. Kaplan-Meier analyses evaluated prior OC use relative to all-cause and CVD mortality. Cox regression analyses adjusted for baseline differences. Mediation, interaction, and multicollinearity were analyzed. Results: Our 686 women had a mean age 62.5 +/- 9.6 years, multiple cardiac risk factors, and 39% previously used OC. Prior OC users were younger, with less lipid-lowering medication use and lower atherosclerotic CAD severity scores (all p < 0.05). Prior OC use was associated with lower 10-year all-cause (p = 0.007) and CVD mortality (p = 0.019). After adjustment, this was no longer significant (p = 0.77 and p = 0.90, respectively). Atherosclerotic CAD severity score mediated one-third of the observed association. Prior OC use was associated with increased CVD mortality among women with very elevated menopausal systolic blood pressure (SBP). Conclusions: Unadjusted prior OC use was associated with lower longer-term all-cause and CVD mortality. One-third of this observed effect appears mediated by the atherosclerotic CAD severity score. Prior OC was adversely associated with CVD mortality in women with very elevated menopausal SBP. Additional investigation is needed to understand the potential benefits and harms of prior OC use. Clinical Trial Number: NCT00000554, or https://www.clinicaltrials.gov/ct2/show/NCT00000554
引用
收藏
页码:377 / 384
页数:8
相关论文
共 26 条
[1]  
[Anonymous], 2010, Obstet Gynecol, V115, P206, DOI 10.1097/AOG.0b013e3181cb50b5
[2]   Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: A meta-analysis [J].
Baillargeon, JP ;
McClish, DK ;
Essah, PA ;
Nestler, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (07) :3863-3870
[3]   The timing hypothesis: Do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? [J].
Bassuk, Shari S. ;
Manson, JoAnn E. .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (05) :794-803
[4]   Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis [J].
Benkhadra, Khalid ;
Mohammed, Khaled ;
Al Nofal, Alaa ;
Leon, Barbara G. Carranza ;
Alahdab, Fares ;
Faubion, Stephanie ;
Montori, Victor M. ;
Abu Dabrh, Abd Moain ;
Hernandez, Jorge Alberto Zuniga ;
Prokop, Larry J. ;
Murad, Mohammad Hassan .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (11) :4021-4028
[5]   Blood Pressure Effects of the Oral Contraceptive and Postmenopausal Hormone Therapies [J].
Boldo, Angela ;
White, William B. .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2011, 40 (02) :419-+
[6]   Past oral contraceptive use and self-reported high blood pressure in postmenopausal women [J].
Chiu, Christine L. ;
Lind, Joanne M. .
BMC PUBLIC HEALTH, 2015, 15
[7]  
Cooper D., 2021, Oral Contraceptive Pills
[8]   Role of GPER in estrogen-dependent nitric oxide formation and vasodilation [J].
Fredette, Natalie C. ;
Meyer, Matthias R. ;
Prossnitz, Eric R. .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2018, 176 :65-72
[9]   Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study [J].
Hannaford, Philip C. ;
Iversen, Lisa ;
Macfarlane, Tatiana V. ;
Elliott, Alison M. ;
Angus, Valerie ;
Lee, Amanda J. .
BRITISH MEDICAL JOURNAL, 2010, 340 :695
[10]   Hormone replacement therapy and the association with coronary heart disease and overall mortality: Clinical application of the timing hypothesis [J].
Hodis, Howard N. ;
Mack, Wendy J. .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2014, 142 :68-75